{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:23:29Z","timestamp":1791404609260,"version":"4.3.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40263-018-0598-1","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T16:34:30Z","timestamp":1545064470000},"page":"99-106","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Alzheimer\u2019s Disease Clinical Trials: Moving Toward Successful Prevention"],"prefix":"10.1007","volume":"33","author":[{"given":"Michael S.","family":"Rafii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,17]]},"reference":[{"key":"598_CR1","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","volume":"1","author":"CL Masters","year":"2015","unstructured":"Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer\u2019s disease. Nat Rev Dis Primers. 2015;1:15056\u20138.","journal-title":"Nat Rev Dis Primers"},{"key":"598_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8:595\u2013608.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"598_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 2010;9(1):119\u201328.","journal-title":"Lancet Neurol."},{"key":"598_CR4","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S1474-4422(12)70227-2","volume":"11","author":"AS Fleisher","year":"2012","unstructured":"Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, Langbaum JB, Ayutyanont N, Roontiva A, Thiyyagura P, et al. Florbetapir PET analysis of amyloid-beta deposition in the presenilin 1 E280A autosomal dominant Alzheimer\u2019s disease kindred: a cross-sectional study. Lancet Neurol. 2012;11:1057\u201365.","journal-title":"Lancet Neurol."},{"key":"598_CR5","doi-asserted-by":"publisher","first-page":"E4502","DOI":"10.1073\/pnas.1317918110","volume":"110","author":"TL Benzinger","year":"2013","unstructured":"Benzinger TL, Blazey T, Jack CR Jr, Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer\u2019s disease. Proc Natl Acad Sci USA. 2013;110:E4502\u20139.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"598_CR6","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","volume":"84","author":"R Sperling","year":"2014","unstructured":"Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer\u2019s disease: implications for prevention trials. Neuron. 2014;84(3):608\u201322.","journal-title":"Neuron."},{"issue":"228","key":"598_CR7","doi-asserted-by":"publisher","first-page":"228fs13","DOI":"10.1126\/scitranslmed.3007941","volume":"6","author":"RA Sperling","year":"2014","unstructured":"Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, Aisen P. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs13.","journal-title":"Sci Transl Med."},{"key":"598_CR8","unstructured":"Food and Drug Administration. Draft guidance for industry. Alzheimer\u2019s disease: developing drugs for the treatment of early stage disease. 2013. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM338287.pdf ."},{"issue":"3","key":"598_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1212\/WNL.0b013e318207b1b9","volume":"76","author":"PS Aisen","year":"2011","unstructured":"Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011;76(3):280\u20136.","journal-title":"Neurology."},{"key":"598_CR10","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:280\u201392.","journal-title":"Alzheimers Dement."},{"key":"598_CR11","unstructured":"Food and Drug Administration. Early Alzheimer\u2019s disease: developing drugs for treatment guidance for industry. 2018. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM596728.pdf ."},{"key":"598_CR12","unstructured":"Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS. Alzheimer\u2019s disease neuroimaging initiative. 2018."},{"key":"598_CR13","unstructured":"European Medicines Agency. Guideline on the clinical investigation of medicines for the treatment of Alzheimer\u2019s disease. https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-clinical-investigation-medicines-treatment-alzheimers-disease-revision-2_en.pdf . Accessed 22 Feb 2018."},{"issue":"Suppl 5","key":"598_CR14","first-page":"S10","volume":"11","author":"P Leber","year":"1997","unstructured":"Leber P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord. 1997;11(Suppl 5):S10\u201321 (discussion S37\u20139).","journal-title":"Alzheimer Dis Assoc Disord."},{"issue":"7","key":"598_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jalz.2015.04.005","volume":"11","author":"MW Weiner","year":"2015","unstructured":"Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Donohue MC, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw L, Thompson PM, Toga AW, Trojanowski JQ, Alzheimer\u2019s Disease Neuroimaging Initiative. Impact of the Alzheimer\u2019s disease neuroimaging initiative, 2004 to 2014. Alzheimers Dement. 2015;11(7):865\u201384.","journal-title":"Alzheimers Dement."},{"issue":"3","key":"598_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131\u201344.","journal-title":"Nat Rev Neurol."},{"issue":"1","key":"598_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jalz.2014.02.004","volume":"11","author":"K Blennow","year":"2015","unstructured":"Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer\u2019s disease. Alzheimers Dement. 2015;11(1):58\u201369.","journal-title":"Alzheimers Dement."},{"issue":"1","key":"598_CR18","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/ana.24546","volume":"79","author":"KA Johnson","year":"2016","unstructured":"Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79(1):110\u20139.","journal-title":"Ann Neurol."},{"key":"598_CR19","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1212\/WNL.42.3.631","volume":"42","author":"PV Arriagada","year":"1992","unstructured":"Arriagada PV, Growdon JH, Hedley-White ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer\u2019s disease. Neurology. 1992;42:631\u20139.","journal-title":"Neurology."},{"issue":"1","key":"598_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jalz.2016.09.014","volume":"13","author":"SE O\u2019Bryant","year":"2017","unstructured":"O\u2019Bryant SE, Mielke MM, Rissman RA, Lista S, Vanderstichele H, Zetterberg H, Lewczuk P, Posner H, Hall J, Johnson L, Fong YL, Luthman J, Jeromin A, Batrla-Utermann R, Villarreal A, Britton G, Snyder PJ, Henriksen K, Grammas P, Gupta V, Martins R, Hampel H. Biofluid based biomarker professional interest area: blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement. 2017;13(1):45\u201358.","journal-title":"Alzheimers Dement."},{"issue":"17","key":"598_CR21","first-page":"1827","volume":"87","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, Palmqvist S, Baker D, Tan Hehir CA, Jeromin A, Hanlon D, Song L, Shaw LM, Trojanowski JQ, Weiner MW, Hansson O, Blennow K. ADNI Investigators. Plasma tau in Alzheimer disease. Neurology. 2016;87(17):1827\u201335.","journal-title":"Plasma tau in Alzheimer disease. Neurology."},{"issue":"5","key":"598_CR22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K. Alzheimer\u2019s Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with alzheimer disease. JAMA Neurol. 2017;74(5):557\u201366.","journal-title":"JAMA Neurol."},{"issue":"7691","key":"598_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor\u00e9 V, Fowler C, Li QX, Martins R, Rowe C, Tomita T, Matsuzaki K, Ishii K, Ishii K, Arahata Y, Iwamoto S, Ito K, Tanaka K, Masters CL, Yanagisawa K. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature. 2018;554(7691):249\u201354.","journal-title":"Nature."},{"issue":"8","key":"598_CR24","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC, Benzinger T, Fagan AM, Patterson BW, Bateman RJ. Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841\u20139.","journal-title":"Alzheimers Dement."},{"issue":"6","key":"598_CR25","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jalz.2014.02.002","volume":"10","author":"JB Langbaum","year":"2014","unstructured":"Langbaum JB, Hendrix SB, Ayutyanont N, Chen K, Fleisher AS, Shah RC, Barnes LL, Bennett DA, Tariot PN, Reiman EM. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2014;10(6):666\u201374.","journal-title":"Alzheimers Dement."},{"issue":"8","key":"598_CR26","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","volume":"71","author":"MC Donohue","year":"2014","unstructured":"Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen PS. Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing; Alzheimer\u2019s Disease Neuroimaging Initiative; Alzheimer\u2019s Disease Cooperative Study. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014;71(8):961\u201370.","journal-title":"JAMA Neurol."},{"key":"598_CR27","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.jalz.2017.01.018","volume":"13","author":"EC Mormino","year":"2017","unstructured":"Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT. Early and late change on the preclinical Alzheimer\u2019s cognitive composite in clinically normal older individuals with elevated \u03b2-amyloid. Alzheimers Dement. 2017;13:1004\u201312.","journal-title":"Alzheimers Dement."},{"issue":"4","key":"598_CR28","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1001\/jamaneurol.2014.3375","volume":"72","author":"RE Amariglio","year":"2015","unstructured":"Amariglio RE, Donohue MC, Marshall GA, Rentz DM, Salmon DP, Ferris SH, et al. Tracking early decline in cognitive functionin older individuals at risk for Alzheimer disease dementia: The Alzheimer\u2019s Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol. 2015;72(4):446\u201354.","journal-title":"JAMA Neurol."},{"issue":"1","key":"598_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","volume":"13","author":"RJ Bateman","year":"2017","unstructured":"Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, Mills S, Paumier K, Quintana M, Salloway SP, Santacruz A, Schneider LS, Wang G, Xiong C. DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network. The DIAN-TU next generation Alzheimer\u2019s prevention trial: adaptive design and disease progression model. Alzheimers Dement. 2017;13(1):8\u201319.","journal-title":"Alzheimers Dement."},{"key":"598_CR30","doi-asserted-by":"publisher","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","volume":"32","author":"O Adolfsson","year":"2012","unstructured":"Adolfsson O, Pihlgren M, Toni N, et al. An effector-reduced anti-\u03b2-amyloid (A\u03b2) antibody with unique binding properties promotes neuroprotection and glial engulfment of A\u03b2. J Neurosci. 2012;32:9677\u201389.","journal-title":"J Neurosci"},{"key":"598_CR31","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.trci.2018.02.002","volume":"4","author":"PN Tariot","year":"2018","unstructured":"Tariot PN, Lopera F, Langbaum JB, Thomas RG, Hendrix S, Schneider LS, Rios-Romenets S, Giraldo M, Acosta N, Tobon C, Ramos C, Espinosa A, Cho W, Ward M, Clayton D, Friesenhahn M, Mackey H, Honigberg L, Sanabria Bohorquez S, Chen K, Walsh T, Langlois C, Reiman EM. Alzheimer\u2019s Prevention Initiative. The Alzheimer\u2019s prevention initiative autosomal-dominant Alzheimer\u2019s disease trial: a study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer\u2019s disease, including a placebo-treated noncarrier cohort. Alzheimers Dement (N Y). 2018;4:150\u201360.","journal-title":"Alzheimers Dement (N Y)."},{"issue":"1","key":"598_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, Ashford E, Retout S, Hofmann C, Delmar P, Klein G, Andjelkovic M, Dubois B, Boada M, Blennow K, Santarelli L, Fontoura P. SCarlet RoAD Investigators. A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimers Res Ther. 2017;9(1):95.","journal-title":"Alzheimers Res Ther."},{"issue":"7618","key":"598_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O\u2019Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature."},{"issue":"9","key":"598_CR34","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1136\/jnnp-2015-312383","volume":"87","author":"J Wang","year":"2016","unstructured":"Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, Dhadda S, Do I, Rabe M, Luthman J, Cummings J, Satlin A. ADCOMS: a composite clinical outcome for prodromal Alzheimer\u2019s disease trials. J Neurol Neurosurg Psychiatry. 2016;87(9):993\u20139.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"598_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrm2101","volume":"8","author":"C Haass","year":"2007","unstructured":"Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101\u201312. https:\/\/doi.org\/10.1038\/nrm2101 .","journal-title":"Nat Rev Mol Cell Biol."},{"key":"598_CR36","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature11283","volume":"488","author":"T Jonsson","year":"2012","unstructured":"Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer\u2019s disease and age-related cognitive decline. Nature. 2012;488:96\u20139.","journal-title":"Nature."},{"issue":"18","key":"598_CR37","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","volume":"378","author":"MF Egan","year":"2018","unstructured":"Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D. Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2018;378(18):1691\u2013703.","journal-title":"N Engl J Med."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-018-0598-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0598-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0598-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T01:13:46Z","timestamp":1605662026000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-018-0598-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,17]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0598-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,17]]},"assertion":[{"value":"17 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to assist in the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MSR has no conflicts of interest that are directly relevant to the content of this article. PSA has received grants from the National Institutes of Health (NIH), Foundation for National Institutes of Health (FNIH) and Alzheimer\u2019s Association and consulting fees from NeuroPhage, Eli Lilly, Merck, Roche, Amgen, Abbvie, Pfizer, Novartis, Janssen, Lundbeck, Biogen, iPerian, Probiodrug, Anavex, Cohbar, Cytox, aTyr and Avanir.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}